medigraphic.com

2014, Number 4

<< Back Next >>

Enf Infec Microbiol 2014; 34 (4)

Streptococcus agalactiae serotype V, first molecular study in Misiones, Argentina

Laczeski M, Novosak M, Quiroga M, Vergara M

Language: Spanish
References: 44
Page: 132-134
PDF size: 207.01 Kb.


ABSTRACT

Background. Streptococcus agalactiae (GBS) serotype V, is one of the most common serotypes associated with invasive infection in adults and neonates. Virulence factors and their association with resistance to macrolides, has already been highlighted.
Material and methods. 14 strains GBS serotype V from a total of 197 were studied. Conventional PCR was used to search for genes for virulence and resistance to macrolides. The sensitivity to these antimicrobials was determined by D-test and CIM.
Results. hylB and bca genes were detected in 100% of the strains. In 78.6% of them 4 or more genes associated with virulence were detected. The 21.43% of the strains were resistant to macrolides (a constitutive phenotype cMLSB and 2 inducible phenotypes iMLSB) and in them the ermB, mefA and ermTR genes were identified.
Conclusions. The high frequency of genes associated with virulence and resistance to macrolides detected in this study of GBS serotype V, encourages us to strengthen epidemiological surveillance strategies of these strains, given the impact they may have in the treatment of infections in patients allergic to penicillin and vaccine design strategies.


REFERENCES

  1. 1.Poyart C, Réglier-Poupet H, Tazi A, Billoët A, Dmytruk N, Bidet P, et al. “Invasive group B Streptococcal infections in infants, France”. Emerg Infect Dis. 2008;14(10):1647- 1649. doi: 10.3201/eid1410.080185.

  2. 2.CDC-Centers for Disease Control and Prevention: “Prevention of perinatal group B: : revised guidelines from CDC”. MMWR Recomm Rep. 2010; 59 (RR-10):1-31.

  3. 3.Oviedo P, Pegels E, Laczeski M, Quiroga M, Vergara M. “Phenotypic and genotypic characterization of Streptococcus agalactiae in pregnant women. First study in a province of Argentina”. Braz J Microbiol. 2013;44(1):253- 258. doi: 10.1590/S1517-83822013005000030.

  4. 4.Infortmación en: http://test.e-legis-ar.msal.gov.ar/leisref/ public/showAct.php?id=7539&word=#%27. Ley Nacional Nº 26.369. 2008. Consultado el 16 de junio de 2014.

  5. 5.Larcher JS1, Capellino F, De Giusto R, Travella C, Balangione FG, Kreiker G, et al. “Group B Streptococcus colonization during pregnancy and prevention of early onset of disease”. Medicina (B Aires). 2005;65(3):201-6.

  6. 6.García SD, Eliseth MC, Lazzo MJ, Copolillo E, Barata AD, de Torres R et al. “Group B Streptococcus carriers among pregnant women”. Rev Argent Microbiol. 2003;35(4):183-187.

  7. 7.Udo EE1, Boswihi SS, Al-Sweih N. “Genotypes and virulence genes in group B Streptococcus isolated in the maternity hospital, Kuwait”. Med Princ Pract. 2013;22(5):453-7. doi: 10.1159/000349932.

  8. 8.Dutra VG, Alves VM, Olendzki AN, Dias CA, de Bastos AF, Santos GO, et al. “Streptococcus agalactiae in Brazil: serotype distribution, virulence determinants and antimicrobial susceptibility”. BMC Infect Dis. 2014;14(1):323-330. doi:10.1186/1471-2334-14-323.

  9. 9.Lindahl G, Stålhammar-Carlemalm M, Areschoug T. “Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens”. Clin Microbiol Rev. 2005;18(1):102-127.

  10. 10.Manning SD, Ki M, Marrs CF, Kugeler KJ, Borchardt SM, Baker CJ, et al. “The frequency of genes encoding three putative group B streptococcal virulence factors among invasive and colonizing isolates”. BMC Infect Dis. 2006;6:116. doi:10.1186/1471-2334-6-116.

  11. 11.Burns G, Plumb J. “GBS public awareness, advocacy, and prevention--what’s working, what’s not and why we need a maternal GBS vaccine”. Vaccine. 2013;31(4):D58- D65. doi: 10.1016/j.vaccine.2013.02.039.

  12. 12.Castor ML, Whitney CG, Como-Sabetti K, Facklam RR, Ferrieri P, Bartkus JM, et al. “Antibiotic resistance patterns in invasive group B streptococcal isolates”. Infect Dis Obstet Gynecol. 2008; 727505. doi: 10.1155/2008/727505.

  13. 13.Le Thomas-Bories I1, Fitoussi F, Mariani-Kurkdjian P, Raymond J, Brahimi N, Bidet P et al. “Clonal relationship between U.S. and French serotype V group B Streptococcus isolates”. J Clin Microbiol. 2001;39(12):4526-8.

  14. 14.Persson E, Berg S, Bevanger L, Bergh K, Valsö-Lyng R, Trollfors B. “Characterisation of invasive group B streptococci based on investigation of surface proteins and genes encoding surface proteins”. Clin Microbiol Infect. 2008;14(1):66-73.

  15. 15.Savoia D, Gottimer C, Crocilla’ C, Zucca M. “Streptococcus agalactiae in pregnant women: phenotypic and genotypic characters”. J Infect. 2008;56(2):120-125. doi: 10.1016/j.jinf.2007.11.007.

  16. 16.Sambrook J, Rusell DW. Cold Sprong Harbor. Molecular Cloning: a Laboratory Manual. NY. 2001; Vols. 1-3.

  17. 17.Cariaga Martinez AE, Zapata PD. Universitaria de Misiones. Protocolos de Extracción de ADN. El Laboratorio de Biología Molecular. Edición Ampliada. Posadas. 2007;23-39.

  18. 18.Corso A, Faccone D, Gagetti P, Pace J, Regueira M, Pace J, et al. “Prevalence of mef and ermB genes in invasive pediatric erythromycin-resistant Streptococcus pneumoniae isolates from Argentina”. Rev Argent Microbiol. 2009;41(1): 29-33.

  19. 19.Faccone D, Lalonardi F, Abel S, Machain M, Errecalde L, Littvik A, et al. “Multiple-Clones of Streptococcus agalactiae harbouring lnuB gene”. J Infect Dev Ctries. 2010;4(9):580-582.

  20. 20.Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement. 2013;33(1):M100S23.

  21. 21.Gherardi G, Imperi M, Baldassarri L, Pataracchia M, Alfarone G, Recchia S et al. “Molecular epidemiology and distribution of serotypes, surface proteins, and antibiotic resistance among group B streptococci in Italy”. J Clin Microbiol. 2007;45(9):2909-2916.

  22. 22.Elliott JA, Farmer KD, Facklam RR. “Sudden increase in isolation of group B streptococci, serotype V, is not due to emergence of a new pulsed-field gel electrophoresis type”. J Clin Microbiol. 1998;36(7):2115-6.

  23. 23.Stephens DS, Modansky M, Erwin M, Elliot J, Facklam RR, et al. “Invasive group B streptococcal disease: the emergence of serotype V. Blumberg HM1” J Infect Dis, Vol. 173, 2, 1996, págs. 365-73.

  24. 24.Al Safadi R, Amor S, Hery-Arnaud G, Spellerberg B, Lanotte P, Mereghetti L, et al. “Enhanced expression of lmb gene encoding laminin-binding protein in Streptococcus agalactiae strains harboring IS1548 in scpB-lmb intergenic region”. PLoS One. 2010;5(5):e10794. doi: 10.1371/journal.pone.0010794.

  25. 25.Martins ER, Andreu A, Correia P, Juncosa T, Bosch J, Ramirez M, et al. “Group B streptococci causing neonatal infections in barcelona are a stable clonal population: 18-year surveillance”. J Clin Microbiol. 2011; 49(8): 2911-2918. doi: 10.1128/JCM.00271-11. Epub 2011 Jun 22.

  26. 26.Hannoun A, Shehab M, Khairallah MT, Sabra A, Abi-Rached R, Bazi T, et al. “Correlation between Group B Streptococcal Genotypes, Their Antimicrobial Resistance Profiles, and Virulence Genes among Pregnant Women in Lebanon”. Int J Microbiol. 2009; 796512. doi: 10.1155/2009/796512.

  27. 27.Dore N, Bennett D, Kaliszer M, Cafferkey M, Smyth CJ. “Molecular epidemiology of group B streptococci in Ireland: associations between serotype, invasive status and presence of genes encoding putative virulence factors”. Epidemiol Infect. 2003;131(2):823-833.

  28. 28.Campelo FA, Pedrosa AC, Antúnez IÁ, Capuz BL. “Phenotypes and mechanisms of resistance to macrolides and lincosamides in Streptococcus agalactiae isolates with clinical significance in an eight-year period (2002- 2010)”. Rev Esp Quimioter. 2012;25(1):42-46.

  29. 29.Famiglietti A, Quinteros M, Pedrari S, Corso A, Marín M, Nicola F, et al. Actualización del Consenso Sobre las Pruebas de Sensibilidad a los Antimicrobianos en Cocos Grampositivos. Buenos Aires, Argentina. SADEBAC- AAM. 2004.

  30. 30.Mensa J, García-Vázquez E, Vila J. “Macrólidos, cetólidos y estreptograminas”. Enferm Infecc Microbiol Clin. 2003;21(4):200-208.

  31. 31.Feng-Ying C. Lin, Parvin H. Azimi, Leonard E. Weisman, Joseph B. Philips III, et al. “Antibiotic Susceptibility Profiles for Group B Streptococci Isolated from Neonates, 1995-1998”. CID. 2000;31:76-80.

  32. 32.Tamariz Ortiz J, Cruz Quintanilla J, Atencia Porras A, Figueroa Tataje J, Horna Quintana G, Guerra Allison H. “Resistencia a Clindamicina Inducida por Eritromicina en Staphylococcus aureus Aislados de Tres Hospitales de Lima, Perú”. Acta Med Peruana. 2009;26(1):12-16.

  33. 33.Pinheiro S1, Radhouani H, Coelho C, Gonçalves A, Carvalho E, Carvalho JA, et al. “Prevalence and mechanisms of erythromycin resistance in Streptococcus agalactiae from healthy pregnant women”. Microb Drug Resist. 2009;15(2):121-4. doi: 10.1089/mdr.2009.0895.

  34. 34.Von Both U, Ruess M, Mueller U, Fluegge K, Sander A, Berner R. “A serotype V clone is predominant among erythromycin-resistant Streptococcus agalactiae isolates in a southwestern region of Germany”. J Clin Microbiol. 2003;41(5):2166-2169.

  35. 35.De Francesco MA, Caracciolo S, Gargiulo F, Manca N. “Phenotypes, genotypes, serotypes and molecular epidemiology of erythromycin-resistant Streptococcus agalactiae in Italy”. Eur J Clin Microbiol Infect Dis, Vol. 2012;31(8):1741-7. doi: 10.1007/s10096-011-1495-4.

  36. 36.Fluegge K, Supper S, Siedler A, Berner R. “Serotype distribution of invasive group B streptococcal isolates in infants: results from a nationwide active laboratory surveillance study over 2 years in Germany”. Clin Infect Dis. 2005; 40(5): 760-763.

  37. 37.Hsueh PR, Teng LJ, Lee LN, Ho SW, Yang PC, Luh KT. “High incidence of erythromycin resistance among clinical isolates of Streptococcus agalactiae in Taiwan”. Antimicrob Agents Chemother. 2001;41(11):3205-3208.

  38. 38.Boswihi SS, Udo EE, Al-Sweih N. “Serotypes and antibiotic resistance in Group B Streptococcus isolated from patients at the Maternity Hospital, Kuwai”t. J Med Microbiol. 2012;61(Pt1):126-31. doi: 10.1099/ jmm.0.035477-0.

  39. 39.DiPersio LP, DiPersio JR. “High rates of erythromycin and clindamycin resistance among OBGYN isolates of group B Streptococcus”. Diagn Microbiol Infect Dis. 2006;54(1):79-82.

  40. 40.Betriu, C., y otros. “Erythromycin and clindamycin resistance and telithromycin susceptibility in Streptococcus agalactiae”. Antimicrob Agents Chemother. 2003;47(3):1112-1114.

  41. 41.Ardanuy C1, Tubau F, Liñares J, Domínguez MA, Pallarés R, Martín R y (G03/103)., “Spanish Pneumococcal Infection Study Network. Distribution of subclasses mefA and mefE of the mefA gene among clinical isolates of macrolide-resistant (M-phenotype) Streptococcus pneumoniae, viridans group streptococci, and Streptococcus pyogenes”. Antimicrob Agents Chemother. 2005;49(2):827-829.

  42. 42.Gygax SE, Schuyler JA, Kimmel LE, Trama JP, Mordechai E, Adelson ME. “Erythromycin and clindamycin resistance in group B Streptococcal clinical isolates”. Antimicrob Agents Chemother. 2006;50(5):1875-1877.

  43. 43.Quiroga M, Pegels E, Oivedo P, Laczeski M, Vergara Marta. “Antimicrobial susceptibility of Streptococcus agalactiae isolated from pregnant women in Misiones, Argentina”. A. Méndez-Vilas, Science against microbial pathogens: communicating current research and technological advances. Badajoz. 2011;444-447.

  44. 44.Chen VL, Avci FY, Kasper DL. “A maternal vaccine against group B Streptococcus: past, present, and future”. Vaccine. 2013;31(4):D13-D19. doi: 10.1016/j. vaccine.2012.12.080.




2020     |     www.medigraphic.com